CAJ | 학술논문

目的研究甲状腺乳头状癌(PTC)中BRAFV600E突变及钠/碘转运体(NIS)的表达,并分析其临床意义.方法对40例PTC标本行BRAFV600E直接测序,检测其突变率；运用免疫组化检测NIS的表达情况.分析BRAFV600E突变与PTC临床病理特征的相关性及NIS的表达与BRAFV600E突变的相关性.结果 BRAFV600E突变率为57.5％；NIS阳性表达率为12.5％.BRAFV600E突变与甲状腺包膜侵犯及肿瘤的复发明显相关(P＜0.05).在BRAFV600E突变的PTC中只有1例NIS阳性表达(4.3％),NIS阳性表达在BRAFV600E突变的PTC中显著降低(P=0.011). 结论 BRAFV600E突变的PTC更具侵袭性、复发率较高及预后差；NIS阳性表达降低,可能是PTC摄碘降低的主要原因.
목적 연구갑상선유두상암(PTC)중BRAFV600E돌변급납/전전운체(NIS)적표체,병분석기림상의의.방법 대40례PTC표본행BRAFV600E직접측서,검측기돌변솔；운용면역조화검측NIS적표체정황.분석BRAFV600E돌변여PTC림상병리특정적상관성급NIS적표체여BRAFV600E돌변적상관성.결과 BRAFV600E돌변솔위57.5％；NIS양성표체솔위12.5％.BRAFV600E돌변여갑상선포막침범급종류적복발명현상관(P＜0.05).재BRAFV600E돌변적PTC중지유1례NIS양성표체(4.3％),NIS양성표체재BRAFV600E돌변적PTC중현저강저(P=0.011). 결론 BRAFV600E돌변적PTC경구침습성、복발솔교고급예후차；NIS양성표체강저,가능시PTC섭전강저적주요원인.
Objective To investigate BRAFV600E mutation and sodium iodide symporter (NIS) expression and its clinical significance in papillary thyroid carcinomas (PTC).Methods BRAFV600E mutation was evaluated by direct sequencing and BRAFV600E mutation was determined in 40 cases of PTC.NIS expression was examined by means of immunohistochemistry.The relationship between BRAFV600E mutation and the clinicopathologic features of PTC was analyzed.The relationship between NIS expression and BRAFV600E mutation in PTC was analyzed.Results Positive BRAFV600E mutation was determined in 23 of 40 cases of PTC (57.5％),whereas positive NIS expression was showed in 7 of 40 cases (12.5％).BRAFV600E mutation was associated with extrathyroid invasion and a high risk of disease recurrence in PTC (P ＜ 0.05).Positive NIS expression was found in only one of 23 cases of PTC with BRAFV600E mutation,and positive NIS expression was associated with a statistically significant lower BRAFV600E mutation in PTC (P =0.011).Conclusions BRAFV600E mutation might be associated with higher aggressiveness,higher disease recurrence and a poorer prognosis.Lower NIS expression may be responsible for poor 131I uptake in